A-Z of Relapse, Recurrence & High-Risk Disease Terms

​​

Advanced Wilms Tumor

Advanced Wilms tumor generally refers to cancer that has spread beyond the kidney or presents with features requiring more intensive treatment. This may include stage 3, stage 4, or certain high-risk forms of disease. Children with advanced Wilms tumor often require a combination of surgery, chemotherapy, radiation therapy, and close follow-up. Advances in pediatric oncology continue to improve outcomes for many children diagnosed with advanced disease.

 

Complete Response (CR)

A Complete Response (CR) occurs when all detectable signs of cancer disappear following treatment. Imaging studies, laboratory investigations, and clinical assessments show no evidence of active disease. Achieving a complete response is a major treatment goal in Wilms tumor care, although ongoing surveillance remains important because recurrence can still occur.

 

Consolidation Therapy

Consolidation therapy refers to additional treatment administered after an initial positive response to help eliminate any remaining cancer cells and reduce the risk of relapse. Depending on the situation, consolidation therapy may involve chemotherapy, radiation therapy, stem cell transplantation, or a combination of approaches. The goal is to strengthen and maintain remission.

 

Disease-Free Interval (DFI)

The Disease-Free Interval (DFI) is the period of time between achieving remission and the return of cancer. The length of the disease-free interval is an important factor when evaluating prognosis and planning treatment for relapsed Wilms tumor. In general, longer disease-free intervals are often associated with more favorable outcomes following recurrence.

 

Disease-Free Survival (DFS)

Disease-Free Survival (DFS) measures the percentage of patients who remain free from detectable cancer after treatment. DFS is commonly used in clinical research to evaluate treatment effectiveness and compare outcomes between different therapies. High disease-free survival rates indicate successful long-term disease control.

 

Distant Recurrence

A distant recurrence occurs when Wilms tumor returns in a part of the body away from the original tumor site. Common locations include the lungs, liver, bones, or brain. Distant recurrence generally requires additional treatment and may involve chemotherapy, surgery, radiation therapy, or clinical trial participation.

 

High-Risk Wilms Tumor

High-risk Wilms tumor refers to disease associated with features that increase the likelihood of recurrence or treatment resistance. Factors contributing to high-risk classification may include diffuse anaplasia, advanced stage, unfavorable treatment response, certain genetic abnormalities, or recurrent disease. High-risk patients often receive more intensive treatment protocols and closer monitoring.

 

Late Relapse

A late relapse occurs when Wilms tumor returns several years after treatment has been completed. Although most recurrences occur within the first few years following diagnosis, late relapse can occasionally develop after extended periods of remission. Continued long-term follow-up helps support early detection and prompt intervention.

 

Local Recurrence

A local recurrence occurs when Wilms tumor returns in or near the original tumor site. Local recurrence may involve the area surrounding the kidney, surgical bed, or nearby tissues. Treatment often depends on the extent of recurrence and may include surgery, chemotherapy, radiation therapy, or combined approaches.

 

Lung Relapse

Lung relapse refers to the return of Wilms tumor within the lungs following previous treatment and remission. Because the lungs are the most common site of metastatic disease in Wilms tumor, they are also a common location for recurrence. Treatment may involve chemotherapy, surgery, radiation therapy, or a combination of modalities depending on the individual situation.

 

Metastatic Relapse

Metastatic relapse occurs when recurrent Wilms tumor is detected in distant organs or tissues. Common sites include the lungs, liver, bones, and brain. Metastatic relapse generally requires more intensive treatment and careful multidisciplinary planning to achieve the best possible outcome.

 

Minimal Residual Disease

Minimal residual disease refers to very small numbers of cancer cells that remain in the body after treatment but cannot be detected through standard imaging or routine testing. Although the concept is more commonly used in blood cancers, the principle of residual microscopic disease remains important in understanding cancer recurrence and relapse risk.

 

Multiple Relapse

Multiple relapse describes a situation in which Wilms tumor returns more than once after previous treatment and remission. Management of multiple relapses can be complex and often requires individualized treatment plans involving specialized pediatric oncology expertise, advanced therapies, and supportive care strategies.

 

Partial Response (PR)

A Partial Response (PR) occurs when treatment significantly reduces the size or extent of cancer but does not completely eliminate all detectable disease. Partial responses are often considered encouraging signs that treatment is working and may be followed by additional therapies aimed at achieving complete remission.

 

Progressive Disease (PD)

Progressive Disease (PD) occurs when cancer continues to grow or spread despite treatment. Progressive disease indicates that the current therapy is not adequately controlling the cancer and often leads to consideration of alternative treatment approaches. Careful monitoring helps identify disease progression as early as possible.

 

Pulmonary Relapse

Pulmonary relapse is another term used to describe recurrence of Wilms tumor within the lungs. Pulmonary relapse remains one of the most common forms of recurrent disease and may be detected through surveillance imaging. Advances in relapse treatment have improved outcomes for many children experiencing lung recurrence.

 

Recurrent Wilms Tumor

Recurrent Wilms tumor refers to cancer that returns after a period during which no detectable disease was present. Recurrence can occur locally, regionally, or at distant sites such as the lungs or liver. Treatment depends on factors including the location of recurrence, previous therapies received, and the child's overall health.

 

Refractory Wilms Tumor

Refractory Wilms tumor describes cancer that fails to respond adequately to standard treatment. Refractory disease may continue to grow despite chemotherapy, surgery, radiation therapy, or other interventions. Management often involves alternative treatment protocols, clinical trials, or specialized therapies designed for resistant disease.

 

Relapse

Relapse is the return of Wilms tumor after treatment has successfully achieved remission. Relapse may occur in the original tumor site, nearby tissues, or distant organs. Although relapse can be challenging, advances in pediatric oncology have expanded treatment options and improved outcomes for many children with recurrent disease.

Relapse Risk

Relapse risk refers to the likelihood that Wilms tumor will return following treatment. Factors influencing relapse risk include tumor stage, histology, treatment response, genetic characteristics, and completeness of tumor removal. Understanding relapse risk helps guide treatment intensity and follow-up strategies.

 

Relapsed Wilms Tumor

Relapsed Wilms tumor is a term used when Wilms tumor returns after a child has completed treatment and achieved remission. Relapse may occur months or years after treatment ends and often requires additional therapy. Many children with relapsed Wilms tumor can still achieve long-term remission with modern treatment approaches.

 

Remission

Remission refers to a period during which there is no evidence of active cancer. Complete remission indicates the disappearance of all detectable disease, while partial remission reflects substantial improvement without complete elimination of cancer. Remission is an important milestone in the treatment journey, but ongoing surveillance remains essential.

Response Assessment

Response assessment is the process of evaluating how well a Wilms tumor responds to treatment. This typically involves imaging studies, pathology review, laboratory testing, and clinical evaluation. Accurate response assessment helps guide treatment decisions and determine whether therapy should continue, change, or conclude.

 

Response to Treatment

Response to treatment describes how effectively cancer responds to therapy. Responses may range from complete remission to partial response, stable disease, or progressive disease. Monitoring treatment response is essential for optimizing care and achieving the best possible outcomes.

 

Salvage Therapy

Salvage therapy refers to treatment given after cancer has relapsed or failed to respond to initial treatment. Salvage therapy may involve different chemotherapy drugs, surgery, radiation therapy, stem cell transplantation, targeted therapies, or participation in clinical trials. The objective is to regain disease control and achieve remission.

 

Second-Line Therapy

Second-line therapy is treatment administered after first-line treatment has failed or when cancer returns. These therapies often involve different drugs or treatment strategies than those used initially. Second-line treatment plays a critical role in the management of relapsed or refractory Wilms tumor.

 

Stable Disease (SD)

Stable Disease (SD) occurs when cancer neither significantly shrinks nor grows following treatment. While stable disease may not represent complete remission, it can indicate that treatment is effectively controlling tumor progression. Ongoing monitoring is required to determine future treatment needs.

 

Stem Cell Rescue

Stem cell rescue is the process of returning previously collected stem cells to the body following high-dose chemotherapy. This procedure helps restore bone marrow function and blood cell production. Stem cell rescue is often associated with autologous stem cell transplantation used in selected cases of relapsed or high-risk Wilms tumor.

 

Third-Line Therapy

Third-line therapy refers to treatment administered when both first-line and second-line therapies have been unsuccessful. Third-line approaches may include alternative chemotherapy combinations, clinical trial participation, investigational therapies, or highly individualized treatment plans. Decisions are typically made by specialized pediatric oncology teams.

 

Treatment Resistance

Treatment resistance occurs when cancer cells develop the ability to survive despite exposure to therapies intended to destroy them. Resistance may be present at diagnosis or develop over time. Understanding treatment resistance is an important area of pediatric oncology research because it influences relapse risk and treatment outcomes.

 

Very High-Risk Wilms Tumor

Very high-risk Wilms tumor refers to disease with particularly aggressive characteristics or an exceptionally high likelihood of recurrence. Examples may include refractory disease, multiple relapses, diffuse anaplasia, or certain unfavorable biological features. Children with very high-risk disease often require highly specialized treatment approaches and intensive multidisciplinary care.

Understanding the medical terms

Maintaining good nutrition and encouraging appropriate physical activity can support recovery and long-term health.